StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel

BLA FilingDeramiocelNegative

AI Analysis

Summary

Capricor Therapeutics faces renewed FDA scrutiny for its resubmitted BLA for Deramiocel after the lead candidate was previously rejected. The FDA panel and staff have raised questions regarding the drug's effectiveness.

Outcome Details

FDA Panel and staff questioned effectiveness of lead candidate; previous rejection occurred last year; resubmitted BLA under review

Importance:7/10

Sentiment:

-0.80

FDA rejectionBLA resubmissionregulatory challengeefficacy concerns

Related Companies

$BTTX $TRAX

Read the original article

Published by GEN - Genetic Engineering & Biotech News on August 3, 2026 12:47 AM

Read Original